There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Intellia Therapeutics (NTLA – Research Report), Exact Sciences (EXAS – Research Report) and Vertex Pharmaceuticals (VRTX – Research Report) with bullish sentiments.
Intellia Therapeutics (NTLA)
Wells Fargo analyst Yanan Zhu maintained a Buy rating on Intellia Therapeutics on January 5 and set a price target of $95.00. The company’s shares closed last Friday at $28.63.
According to TipRanks.com, Zhu is a 4-star analyst with an average return of
Currently, the analyst consensus on Intellia Therapeutics is a Strong Buy with an average price target of $79.60, which is a 176.1% upside from current levels. In a report issued on January 4, Bank of America Securities also maintained a Buy rating on the stock with a $80.00 price target.
See the top stocks recommended by analysts >>
Exact Sciences (EXAS)
In a report released today, Bruce Jackson from Benchmark Co. assigned a Buy rating to Exact Sciences, with a price target of $91.00. The company’s shares closed last Friday at $73.20.
According to TipRanks.com, Jackson is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Exact Sciences with a $92.50 average price target, representing a 31.7% upside. In a report released yesterday, Bank of America Securities also maintained a Buy rating on the stock with a $88.00 price target.
Vertex Pharmaceuticals (VRTX)
Wells Fargo analyst Mohit Bansal maintained a Buy rating on Vertex Pharmaceuticals yesterday and set a price target of $500.00. The company’s shares closed last Friday at $416.50, close to its 52-week high of $418.71.
According to TipRanks.com, Bansal is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Vertex Pharmaceuticals with a $395.22 average price target, which is a -4.8% downside from current levels. In a report issued on January 4, Argus Research also maintained a Buy rating on the stock with a $420.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on NTLA:
- Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key Milestones
- The Smid-cap biotech stocks to own in 2024, according to Bernstein
- Crispr Therapeutics price target raised to $57 from $50 at RBC Capital
- Intellia Therapeutics files automatic mixed securities shelf
- Intellia Therapeutics receives European Union ODD for NTLA-2002
